# Phase 1/2 stomach cancer trials recruiting: 64 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 64 trials in phase 1/2 for stomach cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 stomach cancer trials: 64 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/stomach-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 64
- Recruiting or not yet: 64
- Read on: November 19, 2026

## Trials

The 25 newest of 64, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 27, 2026 | NCT07897227 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897227) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| September 14, 2026 | NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818018) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| June 26, 2026 | NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | XYone Therapeutics, Inc | Phase 1/2 | Recruiting | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670312) |
| April 24, 2026 | NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551362) |
| April 14, 2026 | NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | BigHat Biosciences, Inc. | Phase 1/2 | Recruiting | Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal... | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529808) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 3, 2026 | NCT07509008 | Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Gastric Cancer, Metastatic | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509008) |
| March 6, 2026 | NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453394) |
| February 25, 2026 | NCT07432633 | \[18F\]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Blue Earth Diagnostics | Phase 1/2 | Recruiting | Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432633) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| January 28, 2026 | NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | Beijing Tide Pharmaceutical Co., Ltd | Phase 1/2 | Recruiting | Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer, Malignant... | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371663) |
| January 23, 2026 | NCT07364422 | To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | Onconic Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Gastric Cancer (GC) | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364422) |
| January 21, 2026 | NCT07354711 | A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors | 3H Pharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Lung Cancer, Stomach Cancer | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354711) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| January 12, 2026 | NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | Henan Cancer Hospital | Phase 1/2 | Recruiting | Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer, First-line Therapy... | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334431) |
| January 12, 2026 | NCT07333573 | A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer | Shanghai Zhongshan Hospital | Phase 1/2 | Not yet recruiting | Stage IV Gastric Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333573) |
| September 2, 2025 | NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | One-carbon Therapeutics AB | Phase 1/2 | Recruiting | Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)... | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07151040) |
| August 29, 2025 | NCT07149090 | Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites | Asan Medical Center | Phase 1/2 | Recruiting | STOMACH NEOPLASM, Gastric Cancer, Gastric Cancer Adenocarcinoma Metastatic | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07149090) |
| August 11, 2025 | NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | AstraZeneca | Phase 1/2 | Recruiting | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115043) |
| August 7, 2025 | NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic... | University Medical Center Groningen | Phase 1/2 | Recruiting | Esophageal Carcinoma, Gastric Carcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108855) |
| July 17, 2025 | NCT07070232 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Tumor | 1,438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070232) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| West China Hospital | 2 |
| Essen Biotech | 2 |
| Yonsei University | 2 |
| Asan Medical Center | 2 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 2 |
| Cancer Research UK | 2 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 2 |
| BigHat Biosciences, Inc. | 1 |
| One-carbon Therapeutics AB | 1 |
| [Yuhan Corporation](https://specstream.ai/data/clinical-trials/company/yuhan-corporation) | 1 |
| Shanghai Public Health Clinical Center | 1 |
| Arvinas Inc. | 1 |
| Blue Earth Diagnostics | 1 |
| Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 1 |
| Neonc Technologies, Inc. | 1 |
| DualityBio Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
| Perspective Therapeutics | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| Inhibrx Biosciences, Inc | 1 |
| University Medical Center Groningen | 1 |
| Hadassah Medical Organization | 1 |
| Medsyn Biopharma, LLC | 1 |
| Onconic Therapeutics Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 28 |
| China | 20 |
| South Korea | 13 |
| Australia | 9 |
| United Kingdom | 8 |
| Spain | 7 |
| France | 6 |
| Italy | 5 |
| Netherlands | 5 |
| Japan | 4 |
| Taiwan | 4 |
| Germany | 3 |
| Canada | 3 |
| Puerto Rico | 2 |
| Belgium | 2 |
| Ireland | 2 |
| Singapore | 1 |
| Israel | 1 |
| Turkey (Türkiye) | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Painting contractors in the United States](https://specstream.ai/data/businesses/painting-contractors/united-states)
- [Moroccan restaurants in the United States](https://specstream.ai/data/businesses/moroccan-restaurants/united-states)
- [Logging contractors in the United States](https://specstream.ai/data/businesses/logging-contractors/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Geriatric medicine practices in the United States](https://specstream.ai/data/businesses/geriatric-medicine-practices/united-states)
